Alzheon
- Biotech or pharma, therapeutic R&D
ALZ-801 is an oral amyloid anti-oligomerization small molecule candidate for Alzheimer's Disease, CAA, Dry AMD and other amyloid-related conditions. Results of the placebo-controlled Phase 3 trial favored ALZ-801 over placebo but were not statistically significant. In the primary model there was a highly
significant (p<0.001) interaction effect with baseline disease severity including a
differential effect for MCI and Mild AD stratification groups. Alzheon is seeking partnership to further develop ALZ-801, explore potential regulatory approval and commercialization.
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}